Tumor Necrosis Factor-Alpha Inhibitory Therapy for Non-Infectious Autoimmune Uveitis by Chen, Judy L. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Tumor Necrosis Factor-Alpha 
Inhibitory Therapy for Non-
Infectious Autoimmune Uveitis
Judy L. Chen, Ann-Marie Lobo-Chan,  
Robison Vernon Paul Chan and Pooja Bhat
Abstract
Biologic agents represent a mainstay in the treatment of refractory non-infectious, 
immune-mediated uveitis. Tumor necrosis factor (TNF)-α inhibitors have 
 demonstrated efficacy in inducing and sustaining disease remission in numerous 
systemic inflammatory disorders and their associated uveitic entities. In particular, 
studies have shown that infliximab and adalimumab can induce steroid-free disease 
remission in patients with Behçet’s disease and juvenile arthritis as treatments 
that are superior to conventional disease-modifying immunosuppressive agents. 
Patients receiving anti-TNF-α therapy may experience adverse events and should 
be closely monitored for the development of opportunistic infections, reactivation 
of tuberculosis and hepatitis, demyelinating disease and neuropathies, as well as 
malignancies.
Keywords: TNF-alpha inhibitors, uveitis, ocular inflammation, etanercept, 
infliximab, adalimumab, golimumab, certolizumab
1. Introduction and overview
• Mechanism of action: TNF-α inhibitors suppress the robust systemic and ocular 
inflammatory response triggered by tumor necrosis factor.
• Formulations & application to uveitis: the currently available agents include 
etanercept, a TNF receptor fusion protein that binds TNF-α and TNF-β, as well 
as monoclonal antibodies infliximab, adalimumab, golimumab, and certoli-
zumab that bind and neutralize soluble and transmembrane TNF. TNF-α 
inhibitors have been used efficaciously in uveitis associated with systemic 
disease, most notably Behçet’s disease and juvenile idiopathic arthritis, as well 
as idiopathic intermediate, posterior and panuveitis.
• Adverse effects: important side effects of TNF-α inhibitors include malignancy 
(lymphomas, skin cancer), infections (reactivation of latent tuberculosis and 
hepatitis, fungal and various opportunistic infections), demyelinating dis-
ease, congestive heart failure, induction of auto-antibodies, and injection site 
reactions.
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• Monitoring clinical response and serum anti-drug antibodies: a major concern 
in patients who demonstrate suboptimal response or fail anti-TNF-α therapy 
is the development of drug antibodies, which may warrant switching agents to 
either another TNF antagonist, or alternative immunosuppression.
2. Mechanism of action
2.1 Physiology of TNF
Tumor necrosis factors are pro-inflammatory cytokines that play an integral 
role in innate and adaptive immunity. These factors exist in two forms as TNF-α and 
TNF-β (or lymphotoxin), and were named for in vitro observations of their induc-
tion of tumor cell lysis and necrosis [1]. Also referred to as sentinel cytokines or 
“the body’s fire alarm,” TNFs have since been discovered to initiate the host defense 
response to local injury and infections, notably those caused by mycobacterial, fun-
gal, and other opportunistic pathogens. TNFs are also responsible for formation of 
lymphoid tissue, as well as activation and recruitment of leukocytes, including neu-
trophils and macrophages for granuloma formation [2]. The physiologic functions 
of TNF explain many of the adverse effects associated with TNF blockade, including 
cytopenias; increased risk for infection, particularly reactivation of hepatitis and 
tuberculosis; as well as higher incidence of certain malignancies, discussed in more 
detail later in this chapter. Regulation of TNF is intricate, and encompasses a variety 
Figure 1. 
TNF production, receptor interaction, and signaling (taken with permission from Tracey et al. [2]). 
Stimulation of a TNF-producing cell (top) results in cell surface expression of tmTNF trimers and enzymatic 
cleavage by TACE to release sTNF. Both tmTNF and sTNF can bind to cell surface TNFR1 or TNFR2 on 
a TNF-responsive cell (bottom), initiating signaling pathways that lead to apoptosis or NF-κB activation 
and inflammatory gene activation. The induction of apoptosis by sTNF via TNFR1 involves internalization 
of the ligand-receptor complex and association of death domains (DD) in the cytoplasmic tail of TNFR1 
with adapter proteins and is normally blocked by FADD-like IL-1β–converting enzyme (FLICE). Reverse 
signaling can be initiated by TNFR2 or TNF antagonist binding to cell surface tmTNF, resulting in cytokine 
suppression or apoptosis. Soluble TNF receptors (sTNFR1 and sTNFR2) can be released from a TNF-responsive 
cell following enzymatic cleavage. TNF antagonists bind sTNF and tmTNF to neutralize their effects. 
TACE = tumor necrosis factor-alpha converting enzyme; NF-κβ = nuclear factor kappa β.
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of stimuli, TNF-producing and responsive cells, and feedback loops. Numerous 
immune cells, including activated macrophages, T cells, mast cells, granulocytes, 
and natural killer cells, produce TNF in the form of transmembrane TNF (tmTNF) 
and soluble TNF (sTNF), which is cleaved from tmTNF (Figure 1). Initial produc-
tion of these factors may be triggered by a wide array of stimuli, including microbial 
pathogens, tumor cells, immune complexes, other cytokines, complement factors, 
irradiation, ischemia or hypoxia, and trauma [2].
Ultimately, both tmTNF and sTNF act upon TNF-responsive cells to trigger an 
inflammatory response via membrane-bound TNF receptors 1 and 2 (TNFR1 and 
TNFR2). TNFR1, also known as p55, is constitutively expressed on nearly all cell types 
except erythrocytes. Depending on the metabolic state of the cell, binding of TNFR1 
triggers one of two distinct signaling pathways: (1) activation of nuclear factor 
kappa-β, a family of transcription factors that controls many inflammatory genes, 
or (2) caspase-dependent apoptosis [2]. TNFR2, also known as p75, is preferentially 
expressed on endothelial and hematopoietic cells, and some tumor cells. The subse-
quent pathways at this time are not as well delineated as those for TNFR1, but ongoing 
studies suggest TNFR2 mediates the activity of regulatory and effector CD8+ T cells, 
as well as interleukin production by B cells [3, 4]. In the eye, pigment epithelial cells 
of the iris, the ciliary body, and retina locally express TNFR1 and TNFR2.
Positive and negative feedback loops initiated by TNF-induced factors regulate 
TNF production. Proteolytic cleavage of the extracellular domain of membrane-
bound TNF receptors results in soluble TNF receptors, which bind and neutralize 
Figure 2. 
Downstream effects of TNF depicting the common cascades leading to immune regulation, apoptosis, and 
inflammation (center), as well as biologic activities specific to the pathophysiology of Crohn’s disease, 
rheumatoid arthritis, and psoriasis (taken with permission from Tracey et al. [2]).
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Figure 3. 
Molecular structures of the available TNF inhibitors (taken with permission from Tracey et al. [2]). 
Infliximab is a mouse/human chimeric monoclonal anti-TNF antibody of IgG1 isotype. Adalimumab and 
golimumab are fully human IgG1 monoclonal anti-TNF antibodies. Etanercept is a fusion protein of TNFR2 
(p75) and the Fc region of human IgG1. Certolizumab is a PEGylated Fab’ fragment of a humanized IgG1 
monoclonal anti-TNF antibody. Fv = variable fragment domain; Fcγ1 = crystallizable fragment domain of 
IgG1; CDR = complementarity determining region.
TNF without inciting inflammation [5]. This maintains the amount of circulating 
TNF below pathologic limits, and thus healthy individuals do not typically express 
detectable serum levels of these factors.
2.2 TNF blockade
In immune-mediated disease, high concentrations of TNF induce excessive 
systemic inflammation and organ injury via direct pathogenic effects and produc-
tion of other inflammatory mediators, apoptosis, and tissue destruction (Figure 2). 
TNF-α has been implicated in the pathogenesis of not only uveitis, but also com-
monly associated complications of ocular inflammation, including cystoid macular 
edema and choroidal neovascularization. Increased expression and production of 
TNF-α has been found to be crucial in the induction phase of experimental autoim-
mune uveitis, and inhibition of TNF-α in these experimental models of uveitis 
reduces the incidence and severity of intraocular inflammation [6].
Given the key role of TNF as a mediator of inflammation, its potential as a 
pharmaceutical target for blockade has been recognized, and several agents that 
antagonize TNF and TNF receptors have been created. Etanercept, the sole inhibi-
tor in its class that is not a monoclonal antibody, is a soluble dimeric fusion protein 
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that carries two copies of the ligand-binding portion of the TNF receptor p75 linked 
to the crystallizable fragment (Fc) region of human immunoglobulin G (IgG). This 
forms unstable complexes with and transiently neutralizes both TNF-α and TNF-β, 
in contrast to the other agents that bind only TNF-α.
The remainder of this class comprises monoclonal antibodies that bind both 
sTNF and tmTNF, with certain structural variations between agents (Figure 3). 
Infliximab is a chimeric mouse-human monoclonal antibody, with murine fragment 
antigen-binding regions (Fab) that bind soluble and bound TNF-α to inactivate them. 
Adalimumab and golimumab, on the other hand, also bind soluble and transmem-
brane forms of TNF-α, but are fully human; the absence of non-human components 
renders them less immunogenic and, therefore, less subject to the formation of 
anti-drug antibodies as compared to infliximab. Similarly, certolizumab pegol is 
humanized, but is also distinct from the others in that this compound couples the Fab 
region to polyethylene glycol rather than the Fc region of human IgG. This reduces 
the antigenicity of this agent and increases the half-life of the drug [7]. The absence 
of the Fc portion of human IgG also precludes the typical antibody effector functions 
of complement activation, apoptosis induction, and neutrophil degranulation [2]. 
Further information regarding each of these agents is detailed in the section below.
3. Formulations and their application to uveitis
Currently, TNF inhibitors are approved by the United States Food and Drug 
Administration (FDA) for use in many immune-mediated conditions, including rheu-
matoid arthritis, juvenile arthritis, ankylosing spondylitis, inflammatory bowel disease, 
and psoriasis and psoriatic arthritis. Only adalimumab has been approved currently by 
the FDA for non-infectious intermediate, posterior and panuveitis in adults and children 
older than 2 years of age. Though their use for uveitis is considered off-label, the remain-
ing anti-TNF agents have been routinely used to control ocular inflammation associated 
with systemic disease. These medications have been found to be particularly effective in 
Behçet’s disease and juvenile idiopathic arthritis, as well as intermediate, posterior, and 
panuveitis of idiopathic and other causes. In general, initial response to TNF-α inhibitors 
is more rapid than other immunomodulatory agents, which can take several weeks to 
months to become therapeutic. Recommendations regarding administration and dosing 
of these agents are not specific to the treatment of uveitis, but are derived from rheuma-
tologic literature. Table 1 summarizes the available TNF antagonists.
3.1 Etanercept
Etanercept (Enbrel®, Amgen Wyeth, Immunex Corporation, Thousand Oaks, 
CA, USA) was the first anti-TNF-α agent to be approved by the FDA in 1998 for 
use in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing 
spondylitis, psoriatic arthritis, and plaque psoriasis. The compound consists of a 
humanized, recombinant dimeric fusion of a human Fc molecule and two p75 TNF 
receptors. By binding circulating TNF-α and TNF-β, etanercept prevents binding 
of these factors to cell surface TNF receptors and the subsequent pro-inflammatory 
cascade. Of note, unlike other agents within its class, etanercept does not bind 
tmTNF, and thus does not induce lysis of TNF-producing cells.
3.1.1 Administration
Etanercept is administered as subcutaneous injections dosed 50 mg once weekly 
or 25 mg twice weekly. Higher doses may be used short term in some conditions.
Advances in the Diagnosis and Management of Uveitis
6
3.1.2 Efficacy
Etanercept appears to be inferior to infliximab and adalimumab for the control 
of ocular inflammation and is generally considered inadequate for the treatment 
of uveitis [8]. It should be noted that the present data are mostly small series, and 
no large, prospective head-to-head studies exist comparing effectiveness or safety 
across the TNF-α antagonists. However, use of etanercept has consistently shown 
decreased initial response, greater corticosteroid burden, and higher rates of 
disease recurrence than have been reported with the use of infliximab for uveitis 
[9]. Furthermore, etanercept has been associated with the paradoxical development 
of de novo uveitis and induction of uveitis flares in patients with spondyloarthropa-
thies, rheumatoid arthritis, juvenile idiopathic arthritis, and sarcoidosis [10]. The 
mechanism for this is unclear, but is thought to be related to pharmacokinetic 
Etanercept 
(Enbrel)
Infliximab 
(Remicade)
Adalimumab 
(Humira)
Golimumab 
(Simponi, 
Simponi Aria)
Certolizumab 
(Cimzia)
Structure and 
mechanism of 
action
Dimeric fusion 
protein of TNF 
receptors that 
binds TNF-α 
and TNF-β
Chimeric 
mouse-human 
monoclonal 
antibody that 
binds TNF-α
Fully 
humanized 
monoclonal 
antibody that 
binds TNF-α
Fully 
humanized 
monoclonal 
antibody that 
binds TNF-α
PEGylated 
antigen-
binding 
fragment that 
binds TNF-α
Route of 
administration 
and dosages
Subcutaneous 
injection (50 mg 
weekly or 25 mg 
twice weekly)
Intravenous 
infusion 
(loading: 3–5 
mg/kg at 0, 2, 
and 6 weeks; 
maintenance: 
3–10 mg/kg 
monthly every 
4–8 weeks, 
up to 20 mg/
kg monthly in 
children)
Subcutaneous 
injection 
(80 mg loading 
dose, followed 
by 40 mg every 
1–2 weeks)
Subcutaneous 
injection 
(50 mg 
monthly) or 
intravenous 
infusion 
(loading: 
2 mg/kg at 
weeks 0 and 4; 
maintenance: 
every 8 weeks)
Subcutaneous 
injection 
(loading: 
400 mg at 
weeks 0, 
2, and 4; 
maintenance: 
400 mg 
injections 
monthly, 
or 200 mg 
injections every 
other week)
Approved 
indications
Rheumatoid 
arthritis, 
juvenile 
idiopathic 
arthritis, 
psoriatic 
arthritis, 
ankylosing 
spondylitis
Rheumatoid 
arthritis, 
ankylosing 
spondylitis, 
psoriatic 
arthritis, 
Crohn’s 
disease, 
ulcerative 
colitis
Noninfectious 
intermediate, 
posterior and 
panuveitis; 
rheumatoid 
arthritis, 
juvenile 
idiopathic 
arthritis, 
psoriatic 
arthritis, 
ankylosing 
spondylitis, 
Crohn’s disease, 
ulcerative 
colitis
Rheumatoid 
arthritis, 
ankylosing 
spondylitis, 
psoriatic 
arthritis
Rheumatoid 
arthritis
Adverse events Opportunistic and invasive fungal infections, reactivation of underlying hepatitis and 
tuberculosis infections, malignancies (lymphoma, skin cancers), demyelinating disease, 
congestive heart failure, induction of autoimmunity
Table 1. 
Summary of the available TNF inhibitors, their structures and mechanisms of action, routes and dosages of 
administration, and adverse effects.
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differences between etanercept and other TNF inhibitors, or differences in reverse 
signaling, such as cytokine modulation [2].
3.1.3 Safety
A recent prospective analysis of etanercept, infliximab, and adalimumab 
found that the rate of infection requiring hospitalization, intravenous antibiotics, 
or life-threatening complications or disability is lower with etanercept than with 
infliximab or adalimumab [11].
3.2 Infliximab
Infliximab (Remicade®, Janssen Biotech, Inc., Horsham, PA, USA) was the 
second anti-TNF-α agent to receive FDA approval in 1999 for treatment of rheuma-
toid arthritis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, psoriatic 
arthritis, and plaque psoriasis. This drug is a chimeric mouse-human monoclonal 
antibody that binds and neutralizes both circulating and membrane-bound TNF-α.
3.2.1 Administration
Infliximab is only available as an intravenous infusion. Typical loading regimens 
involve initial doses of 3–5 mg/kg at 0, 2, and 6 weeks, though the loading dos-
ages may vary based on disease etiology and severity. Once a steady state has been 
achieved following the loading period, patients undergo regular infusions approxi-
mately every 4–8 weeks. Maintenance doses may be safely increased to 5–10 mg/
kg monthly, though in JIA, children may require higher doses (up to 20 mg/kg) to 
successfully quell disease [12].
3.2.2 Efficacy
Numerous studies have established the efficacy of infliximab in various etiolo-
gies of uveitis, with the most data supporting its use in Behçet’s disease and juvenile 
idiopathic arthritis. Consistently, infliximab is associated with a decrease in the 
mean corticosteroid dose and immunosuppression load required for management 
of ocular inflammation. Patients with Behçet’s disease-related uveitis and retinal 
vasculitis have been shown to achieve faster resolution of disease with infliximab 
than with local and systemic corticosteroid therapy, or other immunomodulatory 
agents [13, 14]. Markomichelakis et al. performed a prospective, observational 
study of patients with panuveitis secondary to Behçet’s disease who received a 
single dose of infliximab infusion of 5 mg/kg, high-dose methylprednisolone 1 g/
day for 3 days, or intravitreal triamcinolone; infliximab was found to be superior 
to other treatments in terms of decreasing ocular inflammation, and clearing 
retinal vasculitis, retinitis, and cystoid macular edema [13]. Many children with JIA 
and chronic refractory noninfectious uveitis also achieve improvement as well as 
quiescence of disease with the addition of infliximab to methotrexate [15]. A review 
of 16 children on concomitant infliximab (mean dose 8.2 mg/kg with a median 
interval of 5.6 weeks between infusions) and methotrexate therapy found that 
this regimen effectively controlled ocular inflammation over 1 year of follow-up, 
without recurrence of uveitis in 58% of patients [15]. Reports also suggest efficacy 
of infliximab in the treatment of uveitis related to many other conditions, including 
spondyloarthropathies, inflammatory bowel disease, psoriasis, Takayasu disease, 
pars planitis, multifocal choroiditis, birdshot chorioretinopathy, Vogt-Koyanagi-
Harada syndrome, sympathetic ophthalmia, and idiopathic uveitis. Infliximab use 
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has also shown benefit in recalcitrant uveitic cystoid macular edema and diffuse 
subretinal fibrosis [16, 17]. In a study of nine patients with uveitis-related cystoid 
macular edema refractory to conventional immunosuppressive therapy, Schaap-
Fogler et al. reported that after transitioning to infliximab (dosage of 5 mg/kg at 
0, 2, and 6 weeks, followed by administration every 6–8 weeks afterward) or adali-
mumab (dosage of 40 mg every 2 weeks), patients experienced improvement in 
central macular thickness and visual acuities comparable to those on conventional 
immunomodulatory therapy on follow-up at 3, 6, and 12 months [16].
In a small percentage of patients, the formation of human anti-chimeric anti-
bodies, or HACA, may neutralize infliximab and limit its duration of effect. Other 
immunomodulatory agents may be administered concurrently with infliximab to 
reduce the rate of HACA formation. Further discussion regarding the development 
of HACA and approach to patients who have failed therapy is detailed in the section 
“Adverse effects.”
3.2.3 Safety
Infliximab has been associated with significant adverse effects, including serious 
infections, congestive heart failure, pulmonary embolus, induction of autoantibod-
ies, as well as development of a rare lupus-like syndrome [11, 18].
3.3 Adalimumab
Adalimumab (Humira®, AbbVie Inc., North Chicago, IL, USA) is a fully human-
ized monoclonal antibody against TNF-α. Since its approval by the FDA in 2002, 
it has been steadily gaining popularity for its efficacy and relative safety, and now 
serves as a preferred agent within its class. At this time, its approved indications 
include treatment of rheumatoid arthritis, ulcerative colitis, Crohn’s disease, 
psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and juvenile idiopathic 
arthritis. In 2016, it was approved by the FDA for treatment of non-infectious 
intermediate, posterior and panuveitis.
3.3.1 Administration
Adalimumab is delivered in the form of subcutaneous injections with a loading 
dose of 80 mg followed by 40 mg injections at weekly or biweekly intervals.
3.3.2 Efficacy
Numerous studies have shown adalimumab to be efficacious, particularly 
in uveitis associated with spondyloarthropathies, HLA-B27 positive status, and 
juvenile idiopathic arthritis. There also exists moderate-quality evidence for the 
efficacy of adalimumab in Behçet’s disease-associated uveitis, pars planitis, and 
idiopathic posterior uveitis. A multinational randomized controlled trial evaluating 
adalimumab for the treatment of active noninfectious intermediate, posterior, or 
panuveitis despite prednisone therapy revealed significant improvement in anterior 
and posterior chamber inflammation as well as visual acuity [19]. Compared to 
placebo, adalimumab achieved early and sustained disease control after discon-
tinuation of glucocorticoid treatment, with less chance of treatment failure and 
increased median time to treatment failure (24 weeks in adalimumab group versus 
13 weeks in placebo group) [19]. Like infliximab, adalimumab allows for a signifi-
cant reduction in the mean corticosteroid dose and mean immunosuppression load 
required in noninfectious uveitis. Furthermore, adalimumab has been associated 
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with improvement in uveitic macular edema in prospective trials, which may be 
related to a reduction in plasma anti-VEGF levels with therapy [20].
Though less immunogenic than infliximab, adalimumab may still induce the 
formation of anti-drug antibodies in some patients, which may neutralize and limit 
the efficacy of the drug over time.
3.3.3 Safety
Overall, adalimumab is relatively safe for patients, and it is uncommon that the 
drug induces adverse events necessitating its discontinuation. Rates of lupus-like 
syndromes, and demyelinating disease and neuropathies, including optic neuritis, 
have been reportedly lower as compared to infliximab and etanercept. However, use 
of adalimumab still carries the risk of potentially devastating infections, including 
respiratory tract infections and reactivation of tuberculosis.
3.4 Golimumab
Golimumab (Simponi® and Simponi Aria®, Janssen Biotech, Inc., Horsham, PA, 
USA) was approved by the FDA in 2009 for the treatment of moderate to severe 
active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcer-
ative colitis. Like adalimumab, golimumab is a fully human monoclonal antibody.
3.4.1 Administration
Golimumab is delivered either as monthly subcutaneous injections of 50 mg 
each month or as intravenous infusions. Similar to infliximab, the intravenous form 
of golimumab is loaded at 2 mg/kg at weeks 0 and 4 and then maintained with 
infusions every 8 weeks.
3.4.2 Efficacy
A limited number of case series describe success in treating cases of uveitis 
associated with ankylosing spondylitis, HLA-B27 positive status, juvenile idio-
pathic arthritis, and Behçet’s disease after inadequate response to or intolerance of 
other TNF-α inhibitors [21, 22]. In a 2014 study by Miserocchi et al. of 17 affected 
patients, 14 patients experienced improvement in inflammation with golimumab 
therapy, with the majority achieving quiescence and corticosteroid-sparing effect 
over an average follow-up of 21.9 months [21]. Of note, the remaining three subjects 
were deemed non-responders.
3.4.3 Safety
Existing reports on the use of golimumab have not reported a significantly dif-
ferent rate of adverse events compared to that for other TNF inhibitors, though the 
evidence remains scant. Unlike the other TNF inhibitors, it has not been observed to 
cause a lupus-like syndrome.
3.5 Certolizumab pegol
Certolizumab pegol (Cimzia®, UCB, Inc., Smyrna, GA, USA) is approved for 
the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and 
Crohn’s disease. Unlike fellow anti-TNF monoclonal antibodies, this agent is a 
polyethylene glycolated Fab fragment.
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3.5.1 Administration
Certolizumab is initially administered as subcutaneous injections of 400 mg at 
weeks 0, 2, and 4, then continued as 400 mg injections monthly, or 200 mg injec-
tions every other week.
3.5.2 Efficacy
While certolizumab has shown efficacy in the management of systemic inflamma-
tion, limited data exist regarding its utility in uveitis at this time. A single retrospective 
case series of seven patients reports experience in the treatment of chronic immune-
mediated uveitis (Behçet’s disease, ankylosing spondylitis, psoriatic arthritis, and 
idiopathic retinal vasculitis) that had failed other TNF inhibitor therapy due to loss of 
efficacy or development of serious adverse effects. Over a mean follow-up period of 
10.4 months, five of these seven patients developed quiescence with improvement in 
visual acuity and central macular thickness, with benefit seen as early as 1 month after 
initiation of certolizumab [23]. Another study reports decreased incidence of uveitis 
flares with certolizumab comparable to rates reported for other anti-TNF-α agents, but 
did not have sufficient numbers to establish statistical significance [24].
3.5.3 Safety
Existing reports on the use of certolizumab suggest risk for development of 
autoimmunity. It has been associated with a lupus-like syndrome, as well as bilateral 
panuveitis secondary to an ocular sarcoidosis-like reaction in a patient with rheu-
matoid arthritis and no prior history of sarcoidosis; signs and symptoms were noted 
to resolve following cessation of certolizumab in these cases [25, 26].
4. Adverse effects
4.1 Infections
TNF-α plays a crucial role in host immunity against infections, and correspondingly, 
blockade of TNF predisposes individuals to opportunistic infections, as well as reactiva-
tion of latent tuberculosis and hepatitis viruses. Patients on anti-TNF-α treatment also 
experience increased rates of invasive fungal infections, including histoplasmosis and 
coccidioidomycosis. Therefore, prior to initiating therapy, patients should be screened 
for active and latent tuberculosis with skin testing or an interferon gamma release assay, 
with a follow-up chest X-ray should these screening exams return positive. Patients who 
are diagnosed with tuberculosis should be treated for at least 1 month prior to initiat-
ing anti-TNF-α therapy. Hepatitis screening should also be performed before starting 
TNF inhibitors, with preceding hepatitis B vaccination for individuals not immune to 
hepatitis B, and concomitant prophylaxis against hepatitis virus reactivation during 
anti-TNF therapy for those with serologic evidence of hepatitis infection. Finally, pneu-
mococcal and influenza vaccinations should also be considered. Once TNF-α inhibitors 
are started, live vaccines and unpasteurized milk should be avoided to reduce the risk of 
disseminated infection.
4.2 Malignancies
There is conflicting evidence in the literature regarding the risk of new as well 
as recurrence of prior malignancies with TNF-α therapy. Some registries have noted 
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an increased incidence of lymphoma and melanoma in these patients, and the FDA 
issued a black box warning in 2008 regarding potential association between use 
of TNF inhibitors and development of these cancers in children and young adults. 
Other studies report that TNF inhibitors may accelerate diagnosis of cancer in the 
first year of treatment, but may not increase long-term cancer risk [27]. Evidence 
for this may be confounded by the number of underlying conditions and history of 
other immunosuppressant therapy that patients carry. Regardless, patients being 
considered for TNF-α blockade should be informed of this potential risk.
4.3 Demyelinating disease and neuropathies
TNF inhibitors have been associated with central and peripheral neuropathies, 
including demyelinating and vasculitic neuropathies, and the pathogenesis for this 
phenomenon is unknown. A number of series have reported the development of 
Guillain-Barre syndrome and demyelinating lesions in the central nervous system 
similar to those in multiple sclerosis following initiation of anti-TNF-α therapy [28, 
29]. For this reason, an MRI of the brain is recommended for patients with interme-
diate uveitis prior to starting TNF inhibitors to rule out underlying demyelinating 
disease, and these agents should not be prescribed to patients with evidence of 
demyelinating disease. If patients carry a positive family history, the risk of devel-
oping demyelinating disease should be discussed with them before proceeding with 
TNF-α blockers.
4.4 Congestive heart failure
Reports of atherosclerosis formation, promotion of plaque rupture, hypertrophy 
and heart failure from contractile myocardial dysfunction have been described 
with anti-TNF-α blockade. The New York Heart Association (NYHA) recommends 
against the use of TNF inhibitors in patients with NYHA class III or IV heart failure 
[30]. Those patients with compensated congestive heart failure (NYHA classes I 
or II) should undergo a baseline evaluation and be followed closely for any signs of 
worsening heart failure while on anti-TNF-α therapy.
4.5 Induction of autoimmunity
Anti-TNF-α agents may induce autoimmunity and formation of auto-antibodies, 
including antinuclear, anti-DNA, and anti-cardiolipin antibodies, among others. 
All of the TNF inhibitors, especially etanercept, have been associated with the onset 
of sarcoidosis [26, 31]. A rare lupus-like syndrome has been reported with all TNF 
antagonists with the exception of golimumab, and most commonly with etanercept 
and infliximab [32]. Other autoimmune diseases that have been reported include 
leukocytoclastic vasculitis, interstitial lung diseases, antiphospholipid syndrome-
related features, autoimmune hepatitis and uveitis [31].
4.6 Endogenous uveitis
Paradoxically, there are reports associating TNF inhibitors with the onset or recur-
rence of uveitis, particularly with etanercept [33]. The mechanism is unclear, but one 
speculation is that as a soluble receptor, etanercept may prolong the half-life of TNF in 
the eye and potentiate uveitis if the receptor-ligand complex is not cleared promptly. 
Compared to infliximab, etanercept also has differential effects on T-lymphocytes 
and does not induce apoptosis. These differences may also contribute to observations 
of decreased efficacy of etanercept in certain inflammatory conditions [34].
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4.7 Infusion reactions
The most common adverse effects of TNF inhibitor therapy are hypersensitiv-
ity reactions to the drug infusion, which are felt to be related to immune-complex 
formation and deposition. Most reactions are characterized by cutaneous, eczema-
like eruptions at the site of injection, but may also include fever, nausea and vomit-
ing, and arthralgia. These reactions may occur immediately after administration 
or in a delayed fashion up to 2 weeks after treatment. Of note, infliximab has been 
associated with a high rate of hypersensitivity reactions in up to 22% of patients 
undergoing infusion, and has been reported to cause angioedema and anaphylaxis 
[35]. Patients are hence often pre-medicated with Benadryl and acetaminophen to 
prevent these reactions.
4.8 Pregnancy
Pregnancy outcomes for women on infliximab have been reported through 
the Infliximab Safety Database and the Crohn’s Therapy, Resource, Evaluation 
and Assessment Tool (TREAT) registry, without evidence for an increased rate 
of miscarriages, birth complications, or fetal anomalies above that of the general 
pregnant population [36]. As an IgG antibody, infliximab does not cross the 
placenta during the first trimester, but readily crosses during the late second and 
third trimesters, and can subsequently persist in the infant for months after birth 
[37]. Therefore, based upon this and registry-reported outcomes, infliximab is 
generally considered safe during the first trimester and majority of the second 
trimester. However, it is advised that patients stop the drug during the late second 
or third trimester to minimize transfer to the fetus, and to avoid administering 
live vaccines to infants exposed to infliximab in utero given their increased risk for 
disseminated infection.
As a pegylated Fc-free agent, certolizumab does not cross the placenta in signifi-
cant amounts, and is thus thought to be safer in pregnancy [38]. The largest pub-
lished database on certolizumab use in pregnant women to date examined outcomes 
of 1137 prospectively reported pregnancies, without finding increased risk for 
teratogenic effects or fetal death as compared to the general population [38].
5. Monitoring clinical response
Once the decision has been made to proceed with TNF-α blockade, it is impor-
tant to closely monitor patients for clinical response, as well as unwanted secondary 
effects. General routine clinical evaluation for infections, cytopenias, demyelinat-
ing disease, cancer, and cardiovascular alterations is essential, and may need to 
be performed in conjunction with a multidisciplinary team of specialists. Patient 
should also undergo serologic testing with a complete blood count and compre-
hensive metabolic profile every month for the first 3 months and at least every 
2–4 months afterward. If testing results are abnormal, anti-TNF-α therapy should 
be deferred until these parameters have normalized.
The rate of nonresponse has been reported to be approximately 20% for patients 
initiated on infliximab therapy for uveitis [39]. Treatment response may depend on 
various factors, including age, location and severity of uveitis, and type of TNF-α 
blocker used. Genetic polymorphisms in TNF receptors and promoter regions may 
also impact the response to anti-TNF treatment.
Immunogenicity, in which an antigen induces an immune response after being 
recognized by a preexisting T-cell or B-cell receptor, may also occur and account for 
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suboptimal response or treatment failure. This may lead to drug trough levels that 
are lower than expected or the appearance of serum anti-drug antibodies, which 
lead to drug-antibody complex formation and consequent rapid clearance of the 
drug. Ocular and systemic inflammation may subsequently become resistant after 
several months of treatment. This phenomenon is most prevalent with infliximab, 
in which case these antibodies are referred to as human anti-chimeric antibodies 
(HACA), but also occurs with use of adalimumab.
Cordero-Coma and colleagues have summarized a proposal for patients not 
responsive or poorly responsive to anti-TNF therapy based on other studies [40]. 
If a patient is deemed to have insufficient clinical response to anti-TNF-α therapy, 
work-up of these patients with serum drug trough and anti-drug antibody levels 
may be warranted to guide management. High serum drug levels correlate with 
clinical response and decreased risk for relapse, and dosing should be individually 
optimized to attain a therapeutic drug level [41]. In patients with low drug trough 
levels, one should consider intensifying therapy by either increasing the dosage of 
each treatment or the frequency of dosing (up to every 4–6 weeks for infliximab 
and every week for adalimumab). If patients have suboptimal clinical response 
despite sufficient drug trough concentration, an alternative immunosuppressant 
with different mode of action may be required to control disease activity. Regardless 
of serum drug concentration, if anti-drug antibody levels are high, one should 
consider either switching to an alternative TNF inhibitor and/or adding concomi-
tant steroids or other immunosuppression. Studies have shown that the traditional 
approach of intensifying therapy in antibody-positive patients is inferior to switch-
ing agents, with less treatment success and increased expense and risk of adverse 
effects [42].
There is not yet consensus regarding the preferred mode of assessing drug and 
antibody levels. Several assays are available, including enzyme-linked immuno-
sorbent assay (ELISA), radioimmunoassay, reporter gene assay, and homogeneous 
mobility shift assay, each with their own advantages and drawbacks. ELISA is the 
most readily accessible, but suffers from false-positive and false-negative results; 
the other modalities are more precise but logistically difficult to obtain [43].
6. Expert panel recommendations
In 2014, an Expert panel comprising a subcommittee of the American Uveitis 
Society published recommendations regarding the evidence-based use of anti-
TNF-α agents [44]:
• Infliximab and adalimumab can be considered in preference to etanercept, 
which is associated with lower rates of treatment success.
• Infliximab and adalimumab can be considered first-line for treatment of ocular 
manifestations of Behçet’s disease.
• Infliximab and adalimumab can be considered second-line for uveitis associ-
ated with juvenile arthritis.
• Infliximab and adalimumab can be considered potential second-line treat-
ments for severe ocular inflammatory conditions, including posterior or 
panuveitis, severe uveitis associated with seronegative spondyloarthropathy, 
and scleritis in patients who have failed or are not candidates for antimetabo-
lites or calcineurin inhibitors.
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7. Conclusions and future directions
Tumor necrosis factor alpha inhibitors are mainstay treatments for several 
systemic immune-mediated conditions, including rheumatoid arthritis, juvenile 
arthritis, ankylosing spondylitis, inflammatory bowel disease, and psoriatic arthri-
tis, and serve as an important pillar of immunomodulatory therapy in the treatment 
of uveitis. Infliximab and adalimumab have both been shown to be successful at 
controlling ocular inflammation, particularly that related to Behçet’s disease and 
juvenile arthritis. However, serious potential side effects, such as risk for oppor-
tunistic infections, reactivation of latent tuberculosis, and malignancy, may limit 
their use in uveitis. Further studies of the newer agents, golimumab and certoli-
zumab, are warranted to establish their efficacy in uveitis, but early data regarding 
their safety have been promising, and they may represent future additional treat-
ment options within this class.
Future directions for anti-TNF therapy include further studies of the signifi-
cance of intravitreal formulations, as well as the development of biosimilars that 
may represent comparable and more affordable options to the traditional TNF 
antagonists. Intravitreal therapy with anti-TNF agents has been utilized and evalu-
ated in very few studies with small sample sizes. The results have been variable 
and whether local therapy to the eye with these agents is safe and effective remains 
to be seen [45–48]. Biosimilars, defined by the World Health Organization as a 
biotherapeutic product which is similar in terms of quality, safety, and efficacy to 
an already licensed reference biotherapeutic product, provide potential economic 
alternatives to the current TNF-α agents. Despite the effectiveness and relatively 
rapid action of TNF inhibitors, the high cost may hinder accessibility to these drugs 
for some patients. A 2016 systematic review of 19 observational studies and clinical 
trials comparing biosimilar TNF-α inhibitors concluded that evidence supports the 
efficacy and safety of these agents [49]. The most notable existing biosimilar within 
this class is infliximab-dyyb, which exhibits similar qualities to the original product 
infliximab, and is currently available in many countries and was approved by the 
FDA in 2016. Several others are in development or already licensed for use outside 
the United States. As biosimilars become available, they may improve patient acces-
sibility to these drugs for disabling disease.
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